Scarica l'app Stockscreener
2.06
5.64%
0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.95
Aprire:
$1.97
Volume 24 ore:
363.68K
Relative Volume:
0.26
Capitalizzazione di mercato:
$79.23M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-1.8727
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
+3.52%
1M Prestazione:
-34.60%
6M Prestazione:
+21.89%
1 anno Prestazione:
-3.74%
Intervallo 1D:
$1.93
$2.07
Intervallo di 1 settimana:
$1.90
$2.14
Portata 52W:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.06 | 75.00M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
5 Investigational Therapies That Could Change the Parkinson’s Landscape - BioSpace
Bond Watch: Will Atlantica Sustainable Infrastructure plc stock benefit from M AMarket Growth Review & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Final Week: Should I average down on Gain Therapeutics Inc stockNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
Can Gain Therapeutics Inc. stock attract ESG capital inflowsVolatility Adjusted Trading & Free Stay Informed With Forecasts - bollywoodhelpline.com
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6% - MarketBeat
Aug PreEarnings: Can Gain Therapeutics Inc continue delivering strong returnsJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Exit Recap: Is Gain Therapeutics Inc attractive for institutional investors2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Wall Street Recap: Is Gain Therapeutics Inc trading at a discountWeekly Earnings Recap & Consistent Profit Trading Strategies - baoquankhu1.vn
Pullback Watch: What is Gain Therapeutics Incs 5 year growth outlookTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Movement Recap: Can Gain Therapeutics Inc outperform in the next rallyJuly 2025 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Aug Fed Impact: Whats the beta of Gain Therapeutics Inc stockMarket Activity Recap & Fast Entry and Exit Trade Plans - baoquankhu1.vn
EPS Watch: Whats the beta of Gain Therapeutics Inc stock2025 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Aug Intraday: What is Gain Therapeutics Incs TAM Total Addressable MarketJuly 2025 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Why Gain Therapeutics Inc. stock could see breakout soonQuarterly Risk Review & Free Technical Pattern Based Buy Signals - Улправда
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop - Defense World
Reviewing Aldeyra Therapeutics (NASDAQ:ALDX) & Gain Therapeutics (NASDAQ:GANX) - Defense World
How Ideal Power Inc. (5ILA) stock gains from tech spendingJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Улправда
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - Улправда
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Is Gain Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Momentum & Low Risk Growth Stock Ideas - Улправда
Why Gain Therapeutics Inc. stock attracts high net worth investorsDollar Strength & Risk Controlled Daily Plans - Улправда
Published on: 2026-01-09 02:02:08 - Улправда
Stock Recap: Why Gain Therapeutics Inc. stock attracts high net worth investorsEarnings Overview Summary & Verified Momentum Stock Watchlist - Улправда
Can Gain Therapeutics Inc. stock reach $100 price target2025 Earnings Surprises & Daily Profit Maximizing Tips - Улправда
Gain Therapeutics provides additional data from Phase 1b study of GT-02287 - MSN
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker By Investing.com - Investing.com Nigeria
Gain Therapeutics, Inc. to Participate in Key Events During 44th Annual J.P. Morgan Healthcare Conference Week - Quiver Quantitative
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - The Manila Times
Biotech firm Gain Therapeutics lines up three events in San Francisco - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GANX: GT-02287 reduced GluSph by 81% and improved motor scores in Parkinson's disease patients - TradingView — Track All Markets
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker - Investing.com
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - The Manila Times
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - MarketBeat
Research Analysts’ Weekly Ratings Changes for Gain Therapeutics (GANX) - Defense World
GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data - Parkinson's News Today
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Yahoo Finance
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data - Investing.com Canada
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data By Investing.com - Investing.com South Africa
Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase - StocksToTrade
Is Gain Therapeutics Inc. stock a smart buy before Fed meeting2025 Investor Takeaways & Expert Curated Trade Setup Alerts - Улправда
Gain Therapeutics (GANX) Price Target Increased by 11.76% to 7.75 - Nasdaq
Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
US Market Wrap: Why Gain Therapeutics Inc. stock could see breakout soonJuly 2025 Retail & Weekly High Return Forecasts - Улправда
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):